U.S. Markets closed

What Sarepta Therapeutics’ Valuation Trend Indicates

Kenneth Smith
What Sarepta Therapeutics’ Valuation Trend Indicates

Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.